GlassScriptPhysician profile
Keisha L Loftin
NPI 1659327062
$3,898.16
in general payments reported to CMS, 2019-2025
28 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $567 · 2021: $882 · 2022: $551 · 2023: $509 · 2024: $341 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.35 | 2019-2025 | |
| Shield Therapeutics INC | $269.08 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $206.46 | 2024-2025 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $180.57 | 2022-2024 | |
| Exeltis, USA INC. | $136.72 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $136.35 | 2019-2022 | |
| Exact Sciences Corporation | $102.53 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $100.89 | 2019-2022 | |
| Medical Device Business Services, INC. | $95.40 | 2019 | |
| Avion Pharmaceuticals | $89.49 | 2020-2023 | Balcoltra, NP Thyroid 60 |
| Pfizer INC. | $87.38 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $86.56 | 2019 | |
| Myovant Sciences INC. | $78.16 | 2021-2022 | |
| Galderma Laboratories, L.P. | $71.68 | 2024 | |
| Organon LLC | $65.55 | 2023-2024 | Nexplanon |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $49.50 | 2023-2025 | Intrarosa, Femlyv |
| Lupin INC. | $41.82 | 2019-2021 | |
| Astellas Pharma US INC | $39.44 | 2024 | Veozah |
| Duchesnay USA Incorporated | $32.18 | 2019 | |
| Evofem Biosciences, INC. | $30.27 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $29.24 | 2020 | |
| Sage Therapeutics, LLC | $28.79 | 2021 | |
| Hologic Sales and Service, LLC | $24.68 | 2019 | |
| Trevena, INC. | $20.55 | 2021 | |
| Aspira Women'S Health INC | $20.03 | 2024 | Ova1 |
| Daiichi Sankyo INC. | $17.97 | 2019 | |
| Ethicon US, LLC | $17.86 | 2019 | |
| Allergan, INC. | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Loftin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.